Partnership to Develop Anticancer Drugs
By Biotechdaily staff writers
Posted on 08 Jan 2003
A global agreement to co-develop and market new anticancer candidate drugs has been announced by Roche (Basel, Switzerland) and Beaufour Ipsen (Paris, France).Posted on 08 Jan 2003
Beaufour Ipsen has two anticancer drugs in development. One (diflomotecan) is the first of a new generation of topoisomerase-1 inhibitors, while the other (BN80927) has a novel mechanism of action that includes dual inhibition of topoisomerases I and II. Beaufour Ipsen is giving worldwide rights, excluding Europe, to these drugs to Roche. Beaufour retains the European rights. In addition, mutual rights have been granted to future follow-on products, the homocamptothecines, a new class of anticancer molecules discovered by Beaufour Ipsen. The two companies will jointly conduct clinical development of the drugs. Roche will pay Beaufour Ipsen up to US$150 million and additional contingent payments.
"We are delighted to be working with such a world-class company and one of the world's leading oncology companies to develop and market novel topoisomerase inhibitors discovered by Beaufour Ipsen,” said Jean-Luc Belingard, CEO of the Beaufour Ipsen Group.
Related Links:
Roche
Beaufour Ipsen
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Automated MALDI-TOF MS System
EXS 3000
